Ignite Creation Date:
2025-12-24 @ 10:30 PM
Ignite Modification Date:
2026-03-01 @ 9:52 PM
Study NCT ID:
NCT02766335
Status:
COMPLETED
Last Update Posted:
2023-05-25
First Post:
2016-05-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Sponsor:
SWOG Cancer Research Network
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07-31
Start Date Type:
ACTUAL
Primary Completion Date:
2018-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-09
Completion Date Type:
ACTUAL
First Submit Date:
2016-05-06
First Submit QC Date:
None
Study First Post Date:
2016-05-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-05-27
Results First Submit QC Date:
None
Results First Post Date:
2021-12-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-02
Last Update Post Date:
2023-05-25
Last Update Post Date Type:
ACTUAL